Tuesday, February 12, 2019 3:34:14 PM
What happened
Shares of Viking Therapeutics (NASDAQ: VKTX) jumped nearly 14% today after Gilead Sciences (NASDAQ: GILD) announced that a closely watched drug candidate failed a phase 3 trial. The drug candidate, selonsertib, was being developed as a potential treatment for nonalcoholic steatohepatitis (NASH).
The disease is characterized by inflammation and scarring of the liver stemming from fat buildup. The relatively poorly-served patient population has led to over one dozen experimental drugs chasing the market's blockbuster potential. That includes Viking Therapeutics, which no longer has to worry about Gilead Sciences beating it to the punch.
As of 1:51 p.m. EST on Tuesday, Viking's stock had settled to a 10.8% gain.
Gilead Sciences decided to continue developing selonsertib for NASH even after a questionable phase 2 trial failed to show if the drug candidate was actually effective. The highly competitive industry pipeline likely tipped management to make its hasty decision, not to mention mounting pressure following the company's 2016 failure of simtuzumab in clinical trials for the liver disease.
The failure removes Gilead Sciences from contention, which has analysts eyeing the other drug candidates in the field. Viking Therapeutics is developing VK2809, which relies on a different mechanism of action than selonsertib and other drugs.
It delivered impressive results in a phase 2 trial for treating nonalcoholic fatty liver disease (NAFLD), a less-severe form of NASH. After 12 weeks of treatment, fully 67% of patients taking the drug candidate achieved at least a 50% reduction in liver fat. Roughly 83% of patients realized a reduction of at least 30%. Only 18% of patients receiving a placebo saw reductions of either magnitude.
The company thinks that reducing liver fat by at least 30% will be the clinical threshold for treating NASH, so the results in NAFLD suggest the company has a promising treatment in development.
Now what
Viking Therapeutics expects to initiate a trial for VK2809 in NASH sometime this year. Given the impressive results from the midstage trial in NAFLD and the recent failure of Gilead Sciences, the $630 million company is no doubt one of the most promising NASH stocks to watch in 2019. While there are still other deep-pocketed companies developing drug candidates for the liver disease, this small-cap pharma might offer the most reward -- and a healthy amount of risk, too.
https://finance.yahoo.com/news/apos-why-viking-therapeutics-rose-195700888.html
GO VKTX
"PEACE"
Recent VKTX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/21/2024 01:20:57 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/20/2024 08:29:51 PM
- Viking Therapeutics to Participate at Morgan Stanley 22nd Annual Global Healthcare Conference • PR Newswire (US) • 08/28/2024 08:03:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/22/2024 11:23:58 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/21/2024 08:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 12:13:31 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/20/2024 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/31/2024 08:05:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/31/2024 08:05:07 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/30/2024 09:56:42 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/30/2024 09:55:09 PM
- Earnings Updates: Ford Shares Fall 13% on EPS Miss, Stellantis Down 6%, Viking Therapeutics Up 20%, Unilever Up 5% • IH Market News • 07/25/2024 10:19:48 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/24/2024 09:00:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2024 08:10:08 PM
- Viking Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update • PR Newswire (US) • 07/24/2024 08:05:00 PM
- US Index Futures Fall Amid Tech Giant Earnings, Oil Prices Rise • IH Market News • 07/24/2024 09:55:54 AM
- Viking Therapeutics to Report Financial Results for Second Quarter 2024 on July 24, 2024 • PR Newswire (US) • 07/17/2024 08:05:00 PM
- Viking Therapeutics Presents Preclinical Data on Novel Dual Amylin and Calcitonin Receptor Agonists at 84th Scientific Sessions of the American Diabetes Association • PR Newswire (US) • 06/24/2024 11:33:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:10:11 AM
- Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) • PR Newswire (US) • 06/04/2024 11:05:00 AM
- Viking Therapeutics to Participate at Upcoming Investor Conferences • PR Newswire (US) • 05/30/2024 08:03:00 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 05/22/2024 09:12:36 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/22/2024 08:33:26 PM
- Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update • PR Newswire (US) • 04/24/2024 08:05:00 PM
- U.S. Futures Display Mixed Results Amid Earnings, WTI and Brent Crude Prices Dip in June Futures Trading • IH Market News • 04/24/2024 11:31:20 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM